- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
National Quality Forum CEO to Resign
During Corrigan's tenure, the NQF expanded its role into other areas, including within the federal government, said Dr. William Roper, NQF board chairman, in a news release. For instance, in January 2009, NQF was awarded a $10 million-per-year contract from HHS to help develop a portfolio of clinical quality and efficiency measures.
"Originally constituted around serving as a national voluntary consensus standard-setting organization, which remains its core foundational activity, NQF's charge now includes a deeper and broader set of activities designed to help improve the quality and value of American healthcare more rapidly," Roper said in a statement on behalf of the NQF's board.
Read more at: http://tinyurl.com/6p655d6
Source: Modern Healthcare
National Quality Forum President and CEO Janet Corrigan will resign her post in June, after holding the Washington-based organization's top spot since 2006.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
